In the United States, the population aged 65 and older is rapidly growing, and this group uses more healthcare resources and has unique healthcare needs that do not exist in younger populations. However, it was reported that older adults are excluded or underrepresented in clinical trials for several diseases. We examined phase III clinical trials funded by the National Institutes of Health found in www.clinicaltrials.gov from 1965 to 2015 that addressed top causes for hospitalization and/or disability-adjusted life years in older adults: congestive heart failure (n = 45), cardiac dysrhythmias (n = 24), coronary atherosclerosis (n = 106), heart attack (n = 76), stroke (n = 113), chronic obstructive pulmonary disease (n = 14), pneumonia (n = 48), lung cancer (n = 117), prostate cancer (n = 65), and osteoarthritis (n = 15). We then analyzed the representation of older adults in these studies. We found that 33% of studies had arbitrary upper age limits, and 67% of studies reported mean and/or median ages that skewed younger than expected for the disease or condition of interest. Beyond explicit exclusion by age, older adults were often implicitly excluded based on various comorbid conditions such as polypharmacy/concomitant medication (37%) or cardiac issues (30%). We conclude that outcomes of these trials may not be fully generalizable to the general population of older adults. J Am Geriatr Soc 67: 218-222, 2019. 
I
n the United States, the population aged 65 and older is growing rapidly and disproportionately uses healthcare resources. 1 Because older people have unique health circumstances that may not exist in other populations, it may be necessary to consider their complexities when diagnosing and prescribing interventions. Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment (eg, drug, diet, or medical device) is safe and effective in people. However, several authors reported that older adults are excluded or underrepresented in clinical trials for several diseases including osteoarthritis and various types of cancer. [2] [3] [4] [5] [6] Further, there are reports that drug trials in ischemic heart disease do not enroll participants reflective of age-related prevalence of the disease, 7 and another study reported that 21% of all trials analyzed had an age exclusion for people older than 65, 75, or 80 years. 8 Given these concerns, we analyzed how well older adults are represented in recent phase III clinical trials funded by the National Institutes of Health (NIH). These studies are the final hurdle before an intervention reaches the general public. It should therefore have a representative population for the disease or condition under study. Our hypotheses were that older adults would be underrepresented in studies of illnesses that are the top causes for hospitalization and/or disability-adjusted life year (DALYs) in the population; and that underrepresentation would be due to upper age limits for recruitment of participants and exclusion criteria that include illnesses common in the older population.
METHODS

Clinical Trial Sample
For this analysis, we defined older adults as individuals 65 years and older, in keeping with the definition currently used by the Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality (AHRQ), www.clinicaltrials.gov, and multiple other government entities. We examined several of the top diseases and disorders that are associated with hospitalizations and/or affect the DALYs in people 65 years and older, based on AHRQ and World Health Organization data. 9, 10 Using www.clinicaltrials.gov (CT.gov) and PubMed, we identified all NIH-funded clinical trials in these disease areas (n = 4993). We then eliminated all phases other than phase III clinical trials (n = 714) and excluded trials that were open or actively recruiting, yielding a total of 623 trials with active dates between 1965 and 2015. Thus we examined clinical trials focused on congestive heart failure (n = 45), cardiac dysrhythmias (n = 24), coronary atherosclerosis (n = 106), heart attack (n = 76), stroke (n = 113), chronic obstructive pulmonary disease (n = 14), pneumonia (n = 48), lung cancer (n = 117), prostate cancer (n = 65), and osteoarthritis (n = 15).
Assessment of Age of Clinical Trials Participants Reported in Publications
All publications associated with the clinical trials were identified using publicly available data sources (CT.gov, PubMed) and analyzed to determine the mean and median age of participants included within the trial. A publication was matched to a trial based on the National Clinical Trial (NCT) or grant number cited in the publication. The average of the means and medians for all trials related to a particular disease or condition were then calculated and reported.
Determination of Use of Upper Age Limits
To determine if trials had upper age limits, the main study protocol pages on www.clinicaltrials.gov were examined. Only those studies that had "defined age ranges" in the clinical protocol, with minimum and maximum age (eg, 18-65 y), were further analyzed to determine the maximum ages allowed. In this analysis, 33% of the studies had defined age ranges.
Analysis of Exclusion Criteria Reported in Clinical Trial Protocols
Exclusion criteria were captured from clinical trial protocols reported in CT.gov and categorized according to a system developed by the current authors. This system grouped exclusion criteria into the following categories: cancer, cardiovascular, congestive heart failure, diabetes (uncontrolled), diabetes (controlled), dementia/cognition, impairment/psychosis, gastrointestinal/liver, hypertension (uncontrolled), hypertension (controlled), neurologic, pain, physical disability, polypharmacy, pulmonary disease, reduced life expectancy, renal, stroke, and nursing home. Two reviewers independently categorized the exclusion criteria, with periodic cross-comparison checks to compare outcomes and assure consistency in assessments and categorization.
Prevention vs Treatment Analysis
Studies were analyzed to determine whether the primary focus was prevention or treatment. An analysis of the primary purpose of the study (treatment or prevention) was undertaken with the assumption that prevention trials, designed by definition to stop people from getting the disease, would target a younger population. This designation was obtained from the clinical protocol registered in CT.gov.
RESULTS
Age of Clinical Trial Participants
For each disease and condition examined, the mean and median age were collected from publications with a matching Median age, y NCT or grant number. A total of 403 of the 623 trials (67% of the group identified from CT.gov) had identifiable publications. Of these, 83.4% reported mean age and 32.5% reported median age, with some trials reporting both.
As shown in Table 1 , the mean age for studies of lung cancer was 52.4 AE 6.0. In contrast, the mean age for studies of prostate cancer was 65.4 AE 4.6.
Upper Age Limits
A total of 203 (33%) of the 623 studies identified through CT.gov had upper age limits, with the upper limit ranging from 62 to 85 years. Of the studies that had upper age limits, an average of 23% and 55% did not permit people older than 65 or 75 years, respectively, to participate. Specifically, for congestive heart failure, 11 of the 45 total studies had upper age limits. Of those 11 studies, 18% and 64% did not allow people older than 65 years or 75 years to participate, respectively. Exact percentages for each disease can be found in Table 2 .
Exclusion Criteria
Exclusion criteria were identifiable for all 623 of the trials reviewed in the CT.gov database. The most commonly excluded conditions were polypharmacy/concomitant medication (37%), cardiac issues (30%), history of cancer (24%), and various forms of cognitive impairment (20%). These percentages are the average percentages across all diseases in the analysis. The exact percentages for the exclusion criteria across all the diseases can be found in Table 3 .
Treatment vs Prevention
The primary purpose or main reason for each clinical trial was examined from the trial protocol from CT.gov. A total of 68% of the studies were listed as treatment trials; 22% were prevention trials. Of the remaining trials, the primary purpose was unknown/not listed (3.4%), supportive care (3.1%), diagnostic (<2%), health services research (<1%), and screening (<1%).
DISCUSSION
This analysis examined NIH-funded phase III clinical trials for several of the top diseases and disorders that are associated with hospitalizations and/or affect the DALYs in people 65 years and older. We found that exclusion of older adults was done through explicit and implicit exclusion criteria, whether a trial excluded people based on age or through exclusion of conditions common among older adults. This was associated with mean and median ages of subjects in these trials being younger than might otherwise be expected.
In this analysis, 33% of the studies had an upper age limit, with approximately one-quarter of those studies not allowing people age 65 and older to participate. Recruiting a population that is younger than average for the illness is reasonable if the study is focused on prevention. However, 68% of the trials were listed as treatment trials, meaning the trials were designed to help people who have the disease being studied.
If age was not the explicit factor that precluded an older adult from participating in a clinical trial, implicit factors may have prevented participation. Comorbid conditions (eg, hypertension, neurologic disorders, cardiac diseases, renal insufficiency, etc) were frequently listed as exclusion criteria. Additionally, polypharmacy or concomitant medications were other common criteria used for exclusion. The exclusion of these common conditions could lead to limited participation of older adults in trials addressing diseases and disorders prevalent in the population. In fact, in a study of 2010 Medicare beneficiaries, 68.4% had two or more chronic conditions, and 36.4% had four or more chronic conditions.
11
The analysis has some limitations. Although we extensively reviewed publications, it is conceivable that data on mean and median age were not found due to lack of uniform reporting of NCT and grant numbers. For example, of the 623 clinical trials included in this analysis, 191 were completed less than 2 years before this evaluation, with 93 not having publications citing the trial by NCT or grant number. It is unclear whether those trials, and the others for which publications were not identified, did not yet have data reported or if the authors failed to cite the study clearly in reports. The 67% for which data on mean and median age was found is in keeping with findings by Gordon et al that 64% of the cardiac trials funded by the NIH's National Heart, Lung, and Blood Institute reported outcomes data. 12 Another limitation was the inability to determine the appropriateness of exclusion criteria. It is difficult to determine from these data how much of the apparent skewing to younger populations might be medically justified.
Nonetheless, the results of this evaluation are in keeping with previous studies and suggest that NIH-funded phase III clinical trials may disproportionately underrepresent older adults. [2] [3] [4] [5] [6] [7] [8] Concerns regarding adequate inclusion of older populations in clinical studies was one of the concerns of the 21st Century Cures Act, signed into law in December 2016. 13 Among many issues, the law mandated that NIH hold a workshop to examine the inclusion of various populations across the lifespan including pediatric and geriatric populations. NIH has since published the results of Abbreviations: CHD, congestive heart failure; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.
Study protocols were reviewed and examined for specific criteria that would exclude a patient from a particular clinical trial. Shown as percentage of studies that exclude based on specific criteria. 14 and is implementing a new policy that will be effective January 2019. 15, 16 The new policy mandates that all NIH-funded clinical studies include people across the lifespan, as scientifically appropriate. The inclusion mandate will hopefully enhance the recruitment of older adults into clinical trials and yield trial results that are more generalizable to the population with the condition.
